Gillespie Robinson & Grimm Inc. Continues to Hold Position in Bristol-Myers Squibb Company (BMY)
Gillespie Robinson & Grimm Inc. continued to hold its position in Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,039 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Gillespie Robinson & Grimm Inc.’s holdings in Bristol-Myers Squibb were worth $336,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the stock. Welch Investments LLC raised its holdings in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares during the last quarter. Crestwood Advisors Group LLC purchased a new position in shares of Bristol-Myers Squibb in the first quarter worth $116,000. Blue Chip Partners Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the last quarter. Proficio Capital Partners LLC raised its holdings in shares of Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares during the last quarter. Finally, American National Bank raised its holdings in shares of Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 225 shares during the last quarter. 68.88% of the stock is owned by institutional investors.
A number of research firms have issued reports on BMY. Cowen and Company reaffirmed a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday. Hilliard Lyons cut shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target for the company. in a report on Tuesday, September 12th. Jefferies Group LLC raised their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Credit Suisse Group reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a report on Friday, September 8th. Finally, Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 price target for the company. in a report on Thursday, September 7th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $62.20.
Bristol-Myers Squibb Company (NYSE:BMY) remained flat at $63.49 during trading on Thursday. The stock had a trading volume of 2,175,987 shares. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.74. The company has a 50-day moving average price of $58.94 and a 200 day moving average price of $56.02. The firm has a market cap of $104.12 billion, a PE ratio of 23.19 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company’s revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.69 EPS. Analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.46%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
In related news, Director Theodore R. Samuels II acquired 6,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The shares were acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Gillespie Robinson & Grimm Inc. Continues to Hold Position in Bristol-Myers Squibb Company (BMY)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/21/gillespie-robinson-grimm-inc-continues-to-hold-position-in-bristol-myers-squibb-company-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.